Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Adhesion G protein-coupled receptor G1 |
| Gene Name | ADGRG1 |
| Uniprot | Q9Y653 (Human); Q8K209 (Mouse) |
| Synonym | BFPP; BPPR; GPR56; TM7LN4; TM7XN1; 7-transmembrane protein with no EGF-like N-terminal domains-1; G protein-coupled receptor 56; testicular tissue protein Li 77 |
| Background | ADGRG1, also known as G-protein coupled receptor 56 (GPR56) or Protein TM7XN1 (TM7XN1), is a protein encoded by the ADGRG1 gene. It is a member of the adhesion GPCR family, which are characterized by an extended extracellular region often possessing N-terminal protein modules that are linked to a TM7 region via a domain known as the GPCR-Autoproteolysis Inducing (GAIN) domain. It has a 377-residue ECR composed of two domains: an N-terminal pentraxin and laminin/neurexin/sex hormone-binding globulin-like (PLL) domain and a GAIN domain. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX390 | NativeExtract™ Human ADGRG1 Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| S01YF-0723-KX158 | MemDX™ Recombinant Human ADGRG1 Membrane Protein in Virus-Like Particles (MP-VLPs) | HEK293 cell | Full length | VLPs |
| MP0978J | MemDX™ Membrane Protein Human ADGRG1 (Adhesion G protein-coupled receptor G1) for Antibody Discovery | HEK293 cell | Full length | N/A |
| S01YF-0423-KX695 | MemDX™ Membrane Protein Human ADGRG1 (26-402aa) Expressed in HEK293, C-6×His tag | HEK293 cell | Partial | N/A |
| MPX0021K | MemDX™ Membrane Protein Human ADGRG1 Expressed in CHO for Antibody Discovery, Partial (26-342aa) | CHO cell | Partial | N/A |
| Please for more products or customization | ||||
A***ra: The recombinant ADGRG1 exhibited outstanding purity in our GPCR assays.
24/Feb/2023
El***n: Creative Biolabs' responsive technical team addressed specificity requirements swiftly.
07/Aug/2023
We provide tailored solutions to meet your specific requirements. Please for more services.
Gene Editing
Creative Biolabs offers gene editing services. Gene editing systems enable site-specific knockout or transcriptional activation of ADGRG1, a G protein-coupled receptor implicated in tumor angiogenesis and fibrosis. For instance, homology-directed repair templates can be engineered to disrupt ADGRG1's ligand-binding domain, thereby attenuating its pro-oncogenic signaling in preclinical glioblastoma models. Creative Biolabs' expertise in gene editing design ensures high specificity and minimal off-target effects, a critical consideration for clinical translation.
AAV-Mediated ADGRG1 Knockdown for Metabolic Disorders
Creative Biolabs offers AAV-mediated ADGRG1 knockdown services. Recombinant adeno-associated virus (AAV) vectors encoding shRNAs or antisense oligonucleotides offer potent ADGRG1 silencing in metabolically active tissues like liver and adipose. In murine models of non-alcoholic steatohepatitis (NASH), intrahepatic delivery of ADGRG1-targeted AAV9 vectors reduced hepatic inflammation and fibrosis by 40–60% through inhibition of the receptor's interaction with extracellular matrix components. Tropism-engineered AAV capsids further enhance tissue selectivity, minimizing systemic exposure. Creative Biolabs' proprietary AAV capsid library enables customized vector design, ensuring maximal transduction efficiency for ADGRG1 modulation.
Creative Biolabs offers comprehensive and innovative services to drive the development of ADGRG1 cell therapy. Please for more services.
CAR-T Cell Engineering Targeting ADGRG1-Expressing Malignancies
Creative Biolabs offers CAR-T cells development services. Chimeric antigen receptor (CAR)-T cells engineered to recognize ADGRG1's extracellular epitopes demonstrate potent cytotoxicity against solid tumors, including triple-negative breast cancer (TNBC). Preclinical data reveal that third-generation CAR-T constructs incorporating 4-1BB co-stimulatory domains induce durable tumor regression in xenograft models, with a 70% reduction in metastatic burden. Critical to success is the identification of ADGRG1-specific scFv domains devoid of cross-reactivity with homologous receptors. Creative Biolabs' hybridoma development platform accelerates the generation of high-affinity antibodies, a cornerstone for robust CAR-T design.
ADGRG1-Modified MSCs for Fibrosis Resolution
Creative Biolabs offers ADGRG1-modified MSCs development services. Genetic engineering of MSCs to overexpress ADGRG1 enhances their paracrine secretion of anti-fibrotic factors in pulmonary and renal fibrosis models. In a recent study, intratracheal administration of these modified MSCs reduced collagen deposition by 55% in bleomycin-induced lung injury models. Lentiviral transduction protocols optimized for minimal genomic integration ensure both efficacy and safety. Creative Biolabs' stem cell characterization services, including RNA sequencing, validate ADGRG1 expression and functional potency prior to clinical deployment.
Therapeutic targeting of ADGRG1 demands meticulous validation of gene editing efficiency, vector tropism, and cellular specificity. Creative Biolabs' multidisciplinary team offers end-to-end solutions, from target validation to IND-enabling studies. Maximize the translational potential of your ADGRG1 drug candidate. Please feel free to to schedule a consultation with Creative Biolabs' scientists to leverage cutting-edge technologies tailored to your program's unique challenges.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
